To date, the company has raised over $34 million from investors and operates a 15-person team at facilities at Johns Hopkins Medical Campus.
And Schafmeister isn’t the only chemist turning to modular methods of synthesis to explore vast regions of chemical space. It ...
The FDA is reviewing full approval bids for the Duchenne therapies Amondys 45 and Vyondys 53, with decisions expected by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results